<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39402606</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1741-7015</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>BMC medicine</Title><ISOAbbreviation>BMC Med</ISOAbbreviation></Journal><ArticleTitle>Association of COVID-19 with acute and post-acute risk of multiple different complications and mortality in patients infected with omicron variant stratified by initial disease severity: a cohort study in Hong Kong.</ArticleTitle><Pagination><StartPage>461</StartPage><MedlinePgn>461</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">461</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12916-024-03630-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Few studies have attempted to use clinical and laboratory parameters to stratify COVID-19 patients with severe versus non-severe initial disease and evaluate age-specific differences in developing multiple different COVID-19-associated disease outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective cohort included patients from the electronic health database of Hong Kong Hospital Authority between 1 January 2022 and 15 August 2022 until 15 November 2022. The cohort was divided into three cohorts by age (≤ 40, 41-64, and ≥ 65 years old). Each age cohort was stratified into four groups: (1) COVID-19 critically exposed group (ICU admission, mechanical ventilation support, CRP &gt; 80 mg/L, or D-dimer &gt; 2 g/mL), (2) severely exposed group (CRP 30-80 mg/L, D-dimer 0.5-2 g/mL, or CT value &lt; 20), (3) mildly-moderately exposed group (COVID-19 positive-tested but not fulfilling the criteria for the aforementioned critically and severely exposed groups), and (4) unexposed group (without COVID-19). The characteristics between groups were adjusted with propensity score-based marginal mean weighting through stratification. Cox regression was conducted to determine the association of COVID-19 disease severity with disease outcomes and mortality in the acute and post-acute phase (&lt; 30 and ≥ 30 days from COVID-19 infection) in each age group.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 286,114, 320,304 and 194,227 patients with mild-moderate COVID-19 infection; 18,419, 23,678 and 31,505 patients with severe COVID-19 infection; 1,168, 2,261 and 10,178 patients with critical COVID-19 infection, and 1,143,510, 1,369,365 and 1,012,177 uninfected people were identified in aged ≤ 40, 40-64, and ≥ 65 groups, respectively. Compared to the unexposed group, a general trend tending towards an increase in risks of multiple different disease outcomes as COVID-19 disease severity increases, with advancing age, was identified in both the acute and post-acute phases. Notably, the mildly-moderately exposed group were associated with either insignificant risks (aged ≤ 40) or the lowest risks (aged &gt; 40) for the disease outcomes in the acute phase of infection (e.g., mortality risk HR (aged ≤ 40): 1.0 (95%CI: 0.5,2.0), HR (aged 41-64): 2.1 (95%CI: 1.8, 2.6), HR (aged &gt; 65): 4.8 (95%CI: 4.6, 5.1)); while in the post-acute phase, these risks were largely insignificant in those aged &lt; 65, remaining significant only in the elderly (age ≥ 65) (e.g., mortality risk HR (aged ≤ 40): 0.8 (95%CI: (0.5, 1.0)), HR (aged 41-64): 1.1 (95%CI: 1.0,1.2), HR (aged &gt; 65): 1.5 (95%CI: 1.5,1.6)). Fully vaccinated patients were associated with lower risks of disease outcomes than those receiving less than two doses of vaccination.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The risk of multiple different disease outcomes in both acute and post-acute phases increased significantly with the increasing severity of acute COVID-19 illness, specifically among the elderly. Moreover, future studies could improve by risk-stratifying patients based on universally accepted thresholds for clinical parameters, particularly biomarkers, using biological evidence from immunological studies.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Eric Yuk Fai</ForeName><Initials>EYF</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, L02-57 2/F, Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong, SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ran</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathur</LastName><ForeName>Sukriti</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Vincent Ka Chun</ForeName><Initials>VKC</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, L02-57 2/F, Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong, SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Francisco Tsz Tsun</ForeName><Initials>FTT</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, L02-57 2/F, Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong, SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chui</LastName><ForeName>Celine Sze Ling</ForeName><Initials>CSL</Initials><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, L02-57 2/F, Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong, SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong`, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Carlos King Ho</ForeName><Initials>CKH</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, L02-57 2/F, Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong, SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Esther Wai Yin</ForeName><Initials>EWY</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, L02-57 2/F, Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong, SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of Hong Kong Shenzhen Institute of Research and Innovation, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Chak Sing</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong`, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Ian Chi Kei</ForeName><Initials>ICK</Initials><Identifier Source="ORCID">0000-0001-8242-0014</Identifier><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, L02-57 2/F, Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong, SAR, China. wongick@hku.hk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China. wongick@hku.hk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK. wongick@hku.hk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aston Pharmacy School, Aston University, Birmingham, B4 7ET, UK. wongick@hku.hk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med</MedlineTA><NlmUniqueID>101190723</NlmUniqueID><ISSNLinking>1741-7015</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006723" MajorTopicYN="N" Type="Geographic">Hong Kong</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Age-specific association</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Multiple organ complications</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">Severity</Keyword></KeywordList><CoiStatement>CKHW reports receipt of research funding from the EuroQoL Group Research Foundation, the Hong Kong Research Grants Council, and the Hong Kong Health and Medical Research Fund; CSLC has received grants from the Health Bureau of the Hong Kong Government, Hong Kong Research Grant Council, Hong Kong Innovation and Technology Commission, Pfizer, IQVIA, MSD, and Amgen, personal fee from Primevigilance Ltd., outside the submitted work; FTTL has been supported by the RGC Postdoctoral Fellowship under the Hong Kong Research Grants Council; XL has received research grants from the Health Bureau of the Government of the Hong Kong SAR, research and educational grants from Janssen and Pfizer, internal funding from University of Hong Kong, consultancy fee from Merck Sharp &amp; Dohme, speaker fee from Pfizer, unrelated to this work; EWYC has received grants from Research Grants Council of the Hong Kong SAR, Research Fund Secretariat of the Health Bureau of the Hong Kong SAR, National Natural Science Fund of China, Bayer, Bristol-Myers Squibb, Pfizer, Janssen, Novartis, Amgen, AstraZeneca, Takeda, the RGA Reinsurance Company, Narcotics Division of the Security Bureau of the Hong Kong SAR, and the National Health and Medical Research Council Australia; consulting fees from AstraZeneca, Pfizer and Novartis; and honorarium from the Hospital Authority of the Hong Kong SAR and serve as the president of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Hong Kong Regional Chapter, outside the submitted work. ICKW reports research funding from Amgen, Bristol Myers Squibb, Pfizer, Janssen, Bayer, GSK, Novartis, the Hong Kong Research Grants Council of the Government of the Hong Kong SAR, the Hong Kong Health and Medical Research Fund, the National Institute for Health Research in England, the European Commission, and the National Health and Medical Research Council in Australia, consulting fees from IQVIA and World Health Organisation, payment for expert testimony for Appeal Court of Hong Kong and is a non-executive director of Jacobson Medical in Hong Kong, Advance Data Analytics for Medical Science (ADAMS) Limited (HK), Asia Medicine Regulatory Affairs (AMERA) Services Limited and OCUS Innovation Limited (HK, Ireland and UK) a former director of Therakind in England, outside of the submitted work. ICKW reports role as member of Pharmacy and Poisons Board in Hong Kong, the Expert Committee on Clinical Events Assessment Following COVID-19 Immunisation, and the Advisory Panel on COVID-19 Vaccines of the Hong Kong Government. EYFW has received research grants from the Health Bureau of the Government of the Hong Kong SAR, the Hong Kong Research Grants Council of the Government of the Hong Kong SAR, Narcotics Division, Security Bureau of the Government of the Hong Kong SAR, Social Welfare Department, Labour and Welfare Bureau of the Government of the Hong Kong SAR and National Natural Science Foundation of China, outside the submitted work. All other authors report no disclosures relevant to the manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>23</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39402606</ArticleId><ArticleId IdType="pmc">PMC11476291</ArticleId><ArticleId IdType="doi">10.1186/s12916-024-03630-6</ArticleId><ArticleId IdType="pii">10.1186/s12916-024-03630-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021;9(2):129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832375</ArticleId><ArticleId IdType="pubmed">33453162</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam ICH, Wong CKH, Zhang R, Chui CSL, Lai FTT, Li X, et al. Long-term post-acute sequelae of COVID-19 infection: a retrospective, multi-database cohort study in Hong Kong and the UK. EClinicalMedicine. 2023;60: 102000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10173760</ArticleId><ArticleId IdType="pubmed">37197226</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133–46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Parasher A. COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J. 2021;97(1147):312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10017004</ArticleId><ArticleId IdType="pubmed">32978337</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacobucci G. Long covid: Damage to multiple organs presents in young, low risk patients. BMJ. 2020;371: m4470.</Citation></Reference><Reference><Citation>Mansell V, Hall Dykgraaf S, Kidd M, Goodyear-Smith F. Long COVID and older people. Lancet Healthy Longevity. 2022;3(12):e849–54.</Citation><ArticleIdList><ArticleId IdType="pubmed">36480981</ArticleId></ArticleIdList></Reference><Reference><Citation>Singhal S, Kumar P, Singh S, Saha S, Dey AB. Clinical features and outcomes of COVID-19 in older adults: a systematic review and meta-analysis. BMC Geriatr. 2021;21(1):321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8133052</ArticleId><ArticleId IdType="pubmed">34011269</ArticleId></ArticleIdList></Reference><Reference><Citation>Molani S, Hernandez PV, Roper RT, Duvvuri VR, Baumgartner AM, Goldman JD, et al. Risk factors for severe COVID-19 differ by age for hospitalized adults. Sci Rep. 2022;12(1):6568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9050669</ArticleId><ArticleId IdType="pubmed">35484176</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan EYF, Zhang R, Mathur S, Yan VKC, Lai FTT, Chui CSL, et al. Post-acute sequelae of COVID-19 in older persons: multi-organ complications and mortality. J Travel Med. 2023;30(5).</Citation><ArticleIdList><ArticleId IdType="pubmed">37310901</ArticleId></ArticleIdList></Reference><Reference><Citation>Alle S, Kanakan A, Siddiqui S, Garg A, Karthikeyan A, Mehta P, et al. COVID-19 risk stratification and mortality prediction in hospitalized Indian patients: harnessing clinical data for public health benefits. PLoS ONE. 2022;17(3): e0264785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8929610</ArticleId><ArticleId IdType="pubmed">35298502</ArticleId></ArticleIdList></Reference><Reference><Citation>Poudel A, Poudel Y, Adhikari A, Aryal BB, Dangol D, Bajracharya T, et al. D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. PLoS ONE. 2021;16(8): e0256744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389366</ArticleId><ArticleId IdType="pubmed">34437642</ArticleId></ArticleIdList></Reference><Reference><Citation>Varikasuvu SR, Varshney S, Dutt N, Munikumar M, Asfahan S, Kulkarni PP, et al. D-dimer, disease severity, and deaths (3D-study) in patients with COVID-19: a systematic review and meta-analysis of 100 studies. Sci Rep. 2021;11(1):21888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8576016</ArticleId><ArticleId IdType="pubmed">34750495</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang R, Elhusseiny KM, Yeh YC, Sun WZ. COVID-19 ICU and mechanical ventilation patient characteristics and outcomes-a systematic review and meta-analysis. PLoS ONE. 2021;16(2): e0246318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7877631</ArticleId><ArticleId IdType="pubmed">33571301</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220–32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2021;76(4):399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7716340</ArticleId><ArticleId IdType="pubmed">33273026</ArticleId></ArticleIdList></Reference><Reference><Citation>Waudby-West R, Parcell BJ, Palmer CNA, Bell S, Chalmers JD, Siddiqui MK. The association between SARS-CoV-2 RT-PCR cycle threshold and mortality in a community cohort. Eur Respir J. 2021;58(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8246006</ArticleId><ArticleId IdType="pubmed">34172468</ArticleId></ArticleIdList></Reference><Reference><Citation>El Zein S, Chehab O, Kanj A, Akrawe S, Alkassis S, Mishra T, et al. SARS-CoV-2 infection: Initial viral load (iVL) predicts severity of illness/outcome, and declining trend of iVL in hospitalized patients corresponds with slowing of the pandemic. PLoS ONE. 2021;16(9): e0255981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8445469</ArticleId><ArticleId IdType="pubmed">34529675</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626–31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Pang P, et al. Long COVID in patients with mild to moderate disease: do thyroid function and autoimmunity play a role? Endocr Pract. 2021;27(9):894–902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8257401</ArticleId><ArticleId IdType="pubmed">34237471</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Brigham E, O’Toole J, Kim SY, Friedman M, Daly L, Kaplin A, et al. The Johns Hopkins post-acute COVID-19 team (PACT): a multidisciplinary, collaborative, ambulatory framework supporting COVID-19 survivors. Am J Med. 2021;134(4):462-7.e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7801819</ArticleId><ArticleId IdType="pubmed">33444589</ArticleId></ArticleIdList></Reference><Reference><Citation>England N. NHS to offer ‘long covid’sufferers help at specialist centres. NHS England London; 2020.</Citation></Reference><Reference><Citation>Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid-Based Med. 2021;26(3):107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7493072</ArticleId><ArticleId IdType="pubmed">32934000</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Q, Zheng B, Daines L, Sheikh A. Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-covid symptoms. Pathogens. 2022;11(2):269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8875269</ArticleId><ArticleId IdType="pubmed">35215212</ArticleId></ArticleIdList></Reference><Reference><Citation>Smilowitz NR, Nguy V, Aphinyanaphongs Y, Newman JD, Xia Y, Reynolds HR, et al. Multiple biomarker approach to risk stratification in COVID-19. Circulation. 2021;143(13):1338–40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7996053</ArticleId><ArticleId IdType="pubmed">33587646</ArticleId></ArticleIdList></Reference><Reference><Citation>Jassat W, Abdool Karim SS, Mudara C, Welch R, Ozougwu L, Groome MJ, et al. Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study. Lancet Glob Health. 2022;10(7):e961–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9116895</ArticleId><ArticleId IdType="pubmed">35597249</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583–90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Yitbarek GY, Walle Ayehu G, Asnakew S, Ayele FY, Bariso Gare M, Mulu AT, et al. The role of C-reactive protein in predicting the severity of COVID-19 disease: a systematic review. SAGE Open Med. 2021;9:20503121211050756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8516378</ArticleId><ArticleId IdType="pubmed">34659766</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazemi E, Soldoozi Nejat R, Ashkan F, Sheibani H. The laboratory findings and different COVID-19 severities: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob. 2021;20(1):17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7962428</ArticleId><ArticleId IdType="pubmed">33726761</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu HH, Qin C, Chen M, Wang W, Tian DS. D-dimer level is associated with the severity of COVID-19. Thromb Res. 2020;195:219–25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7384402</ArticleId><ArticleId IdType="pubmed">32777639</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz-Ruiz HR, Chimoy-Effio PJ, Vértiz-Osores JJ, Bazán-Mayra JE. Correlation between real-time PCR cycle threshold and clinical classification of COVID-19. Rev Chilena Infectol. 2022;39(1):35–44.</Citation><ArticleIdList><ArticleId IdType="pubmed">35735278</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmaeel HM, Ahmed HA, Elbadry MI, Khalaf AR, Mohammed NA, Mahmoud HA, et al. Coagulation parameters abnormalities and their relation to clinical outcomes in hospitalized and severe COVID-19 patients: prospective study. Sci Rep. 2022;12(1):13155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9340692</ArticleId><ArticleId IdType="pubmed">35915103</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Wang C-Y, Wang S-I, Wei JC-C. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine. 2022;53:53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9366236</ArticleId><ArticleId IdType="pubmed">35971425</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M-T, Baek MS, Kim TW, Jung S-Y, Kim W-Y. Cardiovascular outcomes between COVID-19 and non-COVID-19 pneumonia: a nationwide cohort study. BMC Med. 2023;21(1):394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10588072</ArticleId><ArticleId IdType="pubmed">37858177</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.</Citation><ArticleIdList><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Casals M, Brito-Zerón P, Mariette X. Systemic and organ-specific immune-related manifestations of COVID-19. Nat Rev Rheumatol. 2021;17(6):315–32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8072739</ArticleId><ArticleId IdType="pubmed">33903743</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes-Pacheco M, Silva PL, Cruz FF, Battaglini D, Robba C, Pelosi P, et al. Pathogenesis of multiple organ injury in COVID-19 and potential therapeutic strategies. Front Physiol. 2021;12: 593223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7876335</ArticleId><ArticleId IdType="pubmed">33584343</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam ICH, Zhang R, Man KKC, Wong CKH, Chui CSL, Lai FTT, et al. Persistence in risk and effect of COVID-19 vaccination on long-term health consequences after SARS-CoV-2 infection. Nat Commun. 2024;15(1):1716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10894867</ArticleId><ArticleId IdType="pubmed">38403654</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali AM, Rostam HM, Fatah MH, Noori CM, Ali KM, Tawfeeq HM. Serum troponin, D-dimer, and CRP level in severe coronavirus (COVID-19) patients. Immun Inflamm Dis. 2022;10(3): e582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8926504</ArticleId><ArticleId IdType="pubmed">34939346</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadras O, Afsahi AM, Pashaei Z, Mojdeganlou H, Karimi A, Habibi P, et al. The relationship between COVID-19 viral load and disease severity: a systematic review. Immun Inflamm Dis. 2022;10(3): e580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8926507</ArticleId><ArticleId IdType="pubmed">34904379</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenoy S. SARS-CoV-2 (COVID-19), viral load and clinical outcomes; lessons learned one year into the pandemic: A systematic review. World J Crit Care Med. 2021;10(4):132–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8291003</ArticleId><ArticleId IdType="pubmed">34316448</ArticleId></ArticleIdList></Reference><Reference><Citation>Debi H, Itu ZT, Amin MT, Hussain F, Hossain MS. Association of serum C-reactive protein (CRP) and D-dimer concentration on the severity of COVID-19 cases with or without diabetes: a systematic review and meta-analysis. Expert Rev Endocrinol Metab. 2022;17(1):83–93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8607539</ArticleId><ArticleId IdType="pubmed">34781810</ArticleId></ArticleIdList></Reference><Reference><Citation>Landstra CP, de Koning EJP. COVID-19 and diabetes: understanding the interrelationship and risks for a severe course. Front Endocrinol (Lausanne). 2021;12: 649525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8247904</ArticleId><ArticleId IdType="pubmed">34220706</ArticleId></ArticleIdList></Reference><Reference><Citation>Paranga TG, Pavel-Tanasa M, Constantinescu D, Plesca CE, Petrovici C, Miftode IL, et al. Comparison of C-reactive protein with distinct hyperinflammatory biomarkers in association with COVID-19 severity, mortality and SARS-CoV-2 variants. Front Immunol. 2023;14:1213246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10302717</ArticleId><ArticleId IdType="pubmed">37388734</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisinger C, Kirchberger I, Warm TD, Hyhlik-Dürr A, Goßlau Y, Linseisen J. Elevated plasma D-Dimer concentrations in adults after an outpatient-treated COVID-19 infection. Viruses. 2022;14(11):2441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9699049</ArticleId><ArticleId IdType="pubmed">36366539</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin SM, Huang ACC, Chiu TH, Chang KW, Huang TH, Yang TH, et al. Clinical and laboratory predictors for disease progression in patients with COVID-19: a multi-center cohort study. Biomed J. 2022;46(1):100–9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9674567</ArticleId><ArticleId IdType="pubmed">36414180</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner J, Garcia-Rodriguez V, Yu A, Dutra B, DuPont A, Cash B, et al. Elevated D-Dimer is associated with multiple clinical outcomes in hospitalized COVID-19 patients: a retrospective cohort study. SN Compr Clin Med. 2020;2(12):2561–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7648852</ArticleId><ArticleId IdType="pubmed">33195993</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulou M, Bakola E, Papapostolou A, Stefanou M-I, Gaga M, Zouvelou V, et al. Autonomic dysfunction in long-COVID syndrome: a neurophysiological and neurosonology study. J Neurol. 2022;269(9):4611–2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9086662</ArticleId><ArticleId IdType="pubmed">35536408</ArticleId></ArticleIdList></Reference><Reference><Citation>Marx V. Scientists set out to connect the dots on long COVID. Nat Methods. 2021;18(5):449–53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8081406</ArticleId><ArticleId IdType="pubmed">33911230</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D, Piazza M, Boner AL, Bellanti JA. Long COVID: A proposed hypothesis-driven model of viral persistence for the pathophysiology of the syndrome. Allergy Asthma Proc. 2022;43(3):187–93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9106095</ArticleId><ArticleId IdType="pubmed">35524358</ArticleId></ArticleIdList></Reference><Reference><Citation>DiNicolantonio JJ, McCarty M. Thrombotic complications of COVID-19 may reflect an upregulation of endothelial tissue factor expression that is contingent on activation of endosomal NADPH oxidase. Open Heart. 2020;7(1): e001337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7298678</ArticleId><ArticleId IdType="pubmed">32532805</ArticleId></ArticleIdList></Reference><Reference><Citation>Manly DA, Boles J, Mackman N. Role of tissue factor in venous thrombosis. Annu Rev Physiol. 2011;73:515–25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3076951</ArticleId><ArticleId IdType="pubmed">20690821</ArticleId></ArticleIdList></Reference><Reference><Citation>Miners S, Kehoe PG, Love S. Cognitive impact of COVID-19: looking beyond the short term. Alzheimers Res Ther. 2020;12(1):170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7772800</ArticleId><ArticleId IdType="pubmed">33380345</ArticleId></ArticleIdList></Reference><Reference><Citation>Park YJ, Acosta D, Vassell R, Tang J, Khurana S, Weiss CD, et al. D-dimer and CoV-2 spike-immune complexes contribute to the production of PGE2 and proinflammatory cytokines in monocytes. PLoS Pathog. 2022;18(4): e1010468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9015149</ArticleId><ArticleId IdType="pubmed">35385545</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Clos TW. Function of C-reactive protein. Ann Med. 2000;32(4):274–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10852144</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5908901</ArticleId><ArticleId IdType="pubmed">29706967</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulivarthi S, Gurram MK. Effectiveness of d-dimer as a screening test for venous thromboembolism: an update. N Am J Med Sci. 2014;6(10):491–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4215485</ArticleId><ArticleId IdType="pubmed">25489560</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodríguez C, Luque N, Blanco I, Sebastian L, Barberà JA, Peinado VI, et al. Pulmonary endothelial dysfunction and thrombotic complications in patients with COVID-19. Am J Respir Cell Mol Biol. 2021;64(4):407–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8008805</ArticleId><ArticleId IdType="pubmed">33180562</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>